<DOC>
	<DOCNO>NCT02837003</DOCNO>
	<brief_summary>To evaluate safety reduction dual antiplatelet therapy period three month implantation Ultimaster sirolimus-eluting stent ( U-SES ) . Additionally investigate appropriateness thienopyridine monotherapy discontinuation aspirin .</brief_summary>
	<brief_title>3-Month Discontinuation Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients coronary artery lesion receive percutaneous coronary intervention use Ultimaster sirolimuseluting stent . Patients consider appropriate discontinue dual antiplatelet therapy 3 month stent implantation . Patients provide write informed consent . Patients previously experience stent thrombosis . Patients unable clinical followup procedure specify protocal present study . Patients enrol planned participate another clinical trial antiplatelet therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug-Eluting Stent</keyword>
</DOC>